Elicio Therapeutics, Inc.
US ˙ NasdaqCM ˙ US28657F1030

SecurityELTX / Elicio Therapeutics, Inc.
InstitutionCM Management, LLC
Latest Disclosed Ownership25,000 shares
Latest Disclosed Value $ 267,250
CM Management, LLC ownership in ELTX / Elicio Therapeutics, Inc.

On May 8, 2026 - CM Management, LLC filed a 13F-HR form disclosing ownership of 25,000 shares of Elicio Therapeutics, Inc. (US:ELTX) valued at $267,250 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 25,000 shares of Elicio Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $348,250 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ELICIO THERAPEUTICS COM 28657F103 25,000 0 0.00 267 34.17 0.2234
2026-02-02 2025-12-31 13F ELICIO THERAPEUTICS COM 28657F103 25,000 19,000 316.67 199 206.15 0.1678
2025-11-13 2025-09-30 13F ELICIO THERAPEUTICS COM 28657F103 6,000 -19,000 -76.00 66 -66.32 0.0547
2025-08-12 2025-06-30 13F ELICIO THERAPEUTICS COM 28657F103 25,000 -30,000 -54.55 193 -42.90 0.1758
2025-05-09 2025-03-31 13F ELICIO THERAPEUTICS COM 28657F103 55,000 15,000 37.50 339 65.69 0.3404
2025-02-07 2024-12-31 13F ELICIO THERAPEUTICS COM 28657F103 40,000 -10,000 -20.00 204 -18.73 0.1822
2024-11-12 2024-09-30 13F ELICIO THERAPEUTICS COM 28657F103 50,000 0 0.00 252 22.44 0.2007
2024-08-01 2024-06-30 13F ELICIO THERAPEUTICS COM 28657F103 50,000 -25,000 -33.33 206 -64.04 0.1886
2024-05-14 2024-03-31 13F ELICIO THERAPEUTICS COM 28657F103 75,000 25,000 50.00 570 36.69 0.4788
2024-02-12 2023-12-31 13F ELICIO THERAPEUTICS COM 28657F103 50,000 -15,000 -23.08 417 -24.04 0.3351
2023-11-07 2023-09-30 13F ELICIO THERAPEUTICS COM 28657F103 65,000 0 0.00 549 0.5828
2023-08-04 2023-06-30 13F ELICIO THERAPEUTICS COM 28657F103 65,000 65,000 1 0.6028
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.